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Abstract
Background: The aim of this study was to perform a multicenter, prospective investigation 
regarding the epidemiology, the current effectiveness of therapeutic anticoagulation, and the 
risk of thromboembolism in patients with valvular atrial fibrillation (AF) based on the records 
of the Atrial Fibrillation in Turkey: Epidemiologic Registry (AFTER) study.
Methods: Patients were selected from a total of 2,242 consecutive admissions that presented 
with AF diagnosed via electrocardiogram. Those diagnosed with non-valvular AF were exclu-
ded from the AFTER study population, which left 497 patients with valvular AF for analysis.
Results: The etiology of valvular AF in patients was either attributed to rheumatic mitral 
valve stenosis (n = 217) or possessing a prosthetic heart valve (n = 280). Out of all the patients 
with valvular AF, 83.1% were taking warfarin for anticoagulation. Only 36.1% demonstrated 
a therapeutic international normalized ratio (INR), and among those patients it was found 
that 19.1% exhibited a labile INR. Multivariate analysis revealed that age was the only inde-
pendent predictor of thromboembolic events in patients with valvular AF.
Conclusions: Many valvular AF patients are not maintained at therapeutic INR levels, 
which poses a threat to patient health as they age and are at greater risk for thromboembolism.  
(Cardiol J 2014; 21, 2: 158–162)
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Introduction
The prevalence of atrial fibrillation (AF) and 
AF-related adverse events is growing worldwide 
along with the rise in the elderly population. In fact 
AF is the most common arrhythmia seen in our 
practice [1]. Clinically we subdivide AF into 2 main 
categories including valvular and non-valvular AF, 
www.cardiologyjournal.org 159
Hasan Kaya et al., Valvular atrial fibrillation
which are associated with a 17 and 5 fold increa-
sed risk of stroke per annum, respectively [1, 2]. 
Thromboembolism is the leading cause of AF-related 
adverse events, but it is valvular AF that is associa-
ted with the highest risk of stroke. Even so, most 
studies investigating AF and stroke have been 
mostly performed with non-valvular AF patients. 
This has led to a paucity of detailed epidemiological 
information regarding risk factors for thromboembo-
lism in patients with valvular AF [3–10]. Although 
there was a multicenter study that investigated the 
epidemiology of heart valve diseases in Turkey, this 
study did not focus on valvular AF patients [11]. To 
our knowledge the Atrial Fibrillation in Turkey: Epi-
demiologic Registry (AFTER) multicenter cohort 
study was the first that strived to close the gap in 
knowledge pertaining to the demographic characte-
ristics, attainment of therapeutic international nor-
malized ratio (INR), and risk of thromboembolism 
in patients with valvular AF.
Methods
Study design and patient selection
AFTER is a prospective, multicenter cohort 
study that was designed with the aim to describe 
the epidemiology of AF in Turkey [12]. A total of 
2,242 patients were recruited from 17 hospitals 
so to have representation from the populations 
characteristic of the 7 geographical regions of 
Turkey. This recruitment period took place during 
the period from April 2012 to December 2012 for 
a total duration of about 9 months.
The inclusion criteria were the following: “all 
consecutive patients over 18 years of age who pre-
sented to cardiology outpatient clinics with at least 
one attack of AF identified on electrocardiographic 
examination”. Patients that refused to participate 
in the study or sign the consent form were exclu-
ded. A licensed cardiologist obtained, recorded 
and evaluated patient basic demographic data 
and medications. Every patient was required to 
sign an informed consent document and complete 
a standard registration form. The AFTER study 
was approved by the Ethics Committee.
Descriptions
Types of AF were defined according to the 
European Society of Cardiology (ESC) guidelines 
[1]. Valvular AF was defined as a patient presenting 
with AF and rheumatic mitral valve stenosis or 
prosthetic heart valve(s) [1, 2]. Paroxysmal AF was 
defined as self-terminating and usually lasting from 
48 h to 7 days. Persistent AF was considered an 
episode of AF that either lasts longer than 7 days or 
requires termination by cardioversion. Permanent 
AF was described as AF that occurs on 2 occasions 
within at least 6 months separating each episode 
with no evidence of sinus rhythm in between.
All patients received routine electrocardio-
graphic and echocardiographic examination. Hyper-
tension was defined as a blood pressure measure-
ment greater than 140/90 mm Hg, a prior diagnosis 
of hypertension or requiring antihypertensive 
medication. Diabetes mellitus was designated as 
a fasting blood glucose level greater than 126 mg, 
a prior diagnosis of diabetes or being on anti-
-diabetic therapy. Vascular disease was described as 
having a previous myocardial infarction, a complex 
aortic plaque or peripheral artery disease.
Therapeutic INR range was defined as 2.0–3.0 
in patients with rheumatic mitral valve stenosis 
and aortic prosthetic valves. For patients with 
prosthetic mitral valves or both aortic and mitral 
prosthetic valves, the therapeutic INR range was 
2.5–3.5 [13]. Labile INR was considered attaining 
therapeutic range less than 60% of the time [14].
Statistical analysis
Statistical Package for Social Sciences soft-
ware (SPSS 12, Chicago, IL, USA) was used for 
data analysis. Normality analyses were assessed 
using Kolmogorov-Smirnov and Shapiro-Wilk tests. 
Descriptive parameters were shown as the mean 
± one standard deviation or in percentages. For 
quantitative data comparison, normally distributed 
parameters were compared using Student’s t-test. 
Parameters that did not follow a normal distribution 
were compared using the Mann-Whitney U test. 
The c2 test was used for the comparison of qualita-
tive data. A multivariate logistic regression analysis 
was performed to evaluate the independent predic-
tors of thromboembolic events using age, gender, 
hypertension, heart failure, vascular disease and 
diabetes mellitus as potential covariates. A p-value 
lower than 0.05 was considered significant.
Results
The entire patient cohort with AF numbered 
to 2,242, and after removing patients with non-val-
vular AF the final cohort consisted of 497 patients 
with valvular AF. There were 217 patients with 
rheumatic mitral valve stenosis and 280 patients 
had prosthetic heart valves. Among patients with 
prosthetic valves, 207 (73.9%) of them had mitral 
valve replacement (MVR), 49 (17.5%) had aortic 
valve replacement (AVR) and 24 (8.6%) had both 
MVR and AVR. Valvular AF patient demographics 
are detailed in Table 1. The mean age of these pa-
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tients was 58.4 ± 11.5 years. Among all valvular 
AF patients, 92.2% demonstrated permanent-
-persistent AF. 72% of the AF patients were female. 
Hypertension was the most common comorbid 
condition of 46%. Other frequent comorbidities 
included heart failure, diabetes mellitus and va-
scular disease with frequencies of 21%, 15% and 
9%, respectively. 15% of patients had a history 
of stroke, transient ischemic attack or systemic 
thromboembolism. Conversely, 15.9% of patients 
had a history of bleeding.
About 83% of the patients were taking the oral 
anticoagulant medication warfarin and 36.1% of 
them maintained therapeutic INR levels. However, 
19.1% of the patients that were on warfarin therapy 
demonstrated labile INR.
When comparisons were made between pa-
tients with mitral stenosis vs. those who had 
prosthetic valves, heart failure was more common 
in patients with prosthetic valves (Table 2). Rates 
of stroke and bleeding were similar in both these 
groups. The rate of warfarin use in patients with 
prosthetic valves was higher than in patients with 
rheumatic valvular stenosis (95.4% vs. 67.3%, 
p < 0.001). Patients with MVR demonstrated 
the lowest rates of therapeutic INR achievement 
at 29% as their INRs were suboptimal, ranging 
2.00–2.49. A comparison between warfarin use and 
Table 1. Baseline patient demographics.
Mean age [years] 58.4 ± 11.5
Gender:
Male 139 (28%)
Female 358 (72%)
Age ≥ 75 years 37 (7.4%)
Body mass index [kg/m2] 27.0 ± 4.7
Atrial fibrillation type:
Mitral stenosis 217 (43.7%)
Prosthetic valve 280 (56.3%)
Paroxysmal 39 (7.8%)
Persistent-permanent 458 (92.2%)
Hypertension 227 (45.7%)
Heart failure/LV dysfunction 104 (20.9%)
Type II diabetes mellitus 76 (15.3%)
Vascular disease 44 (8.9%)
Thyroid dysfunction 18 (3.6%)
Smoking 60 (12.1%)
Stroke/TIA/thromboembolism 76 (15.3%)
History of stroke 66 (13.3%)
Bleeding history 79 (15.9%)
Anticoagulant use 413 (83.1%)
Effective INR (n = 413) 149 (36.1%)
Labile INR (n = 413) 79 (19.1%)
Continuous data are expressed as mean ± standard deviation;  
categorical data are expressed as n (%); INR — international nor-
malized ratio; LV — left ventricle; TIA — transient ischemic attack
Table 2. Demographic characteristics of patients with mitral valve stenosis and prosthetic valves.
Variables Mitral stenosis (n = 217) Prosthetic valve (n = 280) P*
Mean age [years] 59.1 ± 11.9 57.9 ± 11.2 0.247
Female 160 (73.7%) 198 (70.7%) 0.457
Body mass index [kg/m2] 27.2 ± 4.9 26.9 ± 4.6 0.403
Atrial fibrillation type: 0.002
Paroxysmal 26 (12%) 13 (5%)
Persistent 41 (19%) 39 (14%)
Permanent 150 (69%) 228 (81%)
Hypertension 102 (47%) 125 (45%) 0.600
Heart failure/LV dysfunction 34 (16%) 70 (25%) 0.011
Diabetes mellitus 34 (16%) 42 (15%) 0.837
Vascular disease 21 (10%) 23 (8%) 0.569
Stroke/TIA/thromboembolism 35 (16%) 41 (15%) 0.648
History of stroke 32 (15%) 34 (12%) 0.396
Bleeding history 30 (14%) 49 (18%) 0.266
Anticoagulant use 146 (67.3%) 267 (95.4%) < 0.001
Effective INR (n = 413) 57 (39%) 92 (35%) 0.354
Labile INR (n = 413) 25 (17%) 54 (20%) 0.444
Ejection fraction [%] 58.3 ± 8.7 51.2 ± 12.8 < 0.001
LA diameter [cm] 5.1 ± 0.9 5.2 ± 0.9 0.461
SEC-thrombus 31 (14%) 12 (4%) < 0.001
Continuous data are expressed as mean ± standard deviation; categorical data are expressed as n (%); *Student’s t-test, Mann-Whitney  
U test and c2 test; INR — international normalized ratio; LV — left ventricle; LA — left atrium; SEC — spontaneous echo contrast;  
TIA — transient ischemic attack
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achievement of therapeutic INR in patients with 
mitral valve stenosis vs. patients with prosthetic 
valves is in Figure 1.
Echocardiographic examinations showed that 
a lower ejection fraction was more common in 
patients with prosthetic valves. However, sponta-
neous echo contrast or thrombus visualization in 
the left atrium was more commonly observed in 
patients with rheumatic mitral valve stenosis. The 
average left atrial diameters were similar between 
both study groups.
Multivariate analysis demonstrated that age 
was the only independent predictor of thrombo-
embolic events (odds ratio 1.034, 95% confidence 
interval 1.009–1.059, p = 0.007). Specifically, each 
year of aging was associated with a 3.4% increase 
in thromboembolic event risk (Table 3).
Discussion
Research in AF has been mostly conducted in 
Western countries, and almost all of these studies 
only involved non-valvular AF patients. Several 
countries that have measured the incidence of 
valvular AF include the United States at 6%, Japan 
at 14% and the AFNET study demonstrated a 9% 
incidence in Germany [5, 7, 15]. In a previous study 
performed in Turkey it was found that valvular AF 
has a frequency of 22%, which likely reflects the 
higher rates of rheumatic heart disease in Turkey 
as compared to other developed nations [3]. In 
a different Turkish multicenter study performed 
with 1,300 patients it was determined that 11% 
had mitral valve stenosis and 13% had prosthetic 
valves [11]. Furthermore, AF was detected in 28% 
of patients with valvular disease, and of patients 
with both AF and valvular disease 38% had mitral 
stenosis. By investigating valvular AF in Turkey, 
we hope to inform the international community 
about its etiology, prevalence, treatment, and the 
risk factors associated with thromboembolism.
According to our findings, one-fifth of AF cases 
were valvular in origin. Rheumatic valvular disease 
made up a slight majority of these cases at 56% 
while prosthetic valves made up the difference at 
44%. Of note, MVR were the most common pros-
thetic heart valves. In fact, valvular AF occurred 
more frequently in females, which may be a re-
flection of the greater likelihood of women having 
mitral stenosis as compared to men. Additionally, 
most patients exhibited permanent AF, and the 
most common comorbid condition was hyperten-
sion in valvular AF patients.
However, one of the most compelling findings 
in our study was poor INR achievement among 
valvular AF patients. Upon analyzing the entire 
cohort in terms of warfarin use, 83.1% of patients 
were taking this anticoagulant. Nevertheless, only 
36.1% of those patients demonstrated a therapeu-
tic INR level. Unfortunately, it was not possible 
to compare our data with other studies, because 
our literature search yielded no papers regarding 
warfarin use and the attainment of effective INR 
for patients with valvular AF.
Subgroup analysis revealed that the highest 
rate of warfarin use was detected in patients with 
both MVR and AVR. Conversely, patients with 
rheumatic mitral valve stenosis had the lowest rate 
of warfarin use. To distinguish between therapeutic 
and suboptimal INRs we adopted the American 
College of Chest Physicians (ACCP) recommen-
dations, because they define INR limits based on 
Figure 1. Comparison of oral anticoagulant use and 
therapeutic international normalized ratio (INR) achie-
vement in patients with mitral stenosis (MS) and pros-
thetic valves; AVR — aortic valve replacement; MVR — 
mitral valve replacement.
Table 3. Logistic regression of the independent 
predictors of stroke/transient ischemic attack/ 
/thromboembolic events.
Variable Odds  
ratio
95% CI P*
Age 1.034 1.009–1.059 0.007
Gender 1.212 0.696–2.113 0.497
Hypertension 1.630 0.960–2.769 0.070
Heart failure 0.935 0.505–1.732 0.830
Vascular disease 0.794 0.337–1.873 0.598
Diabetes mellitus 0.960 0.484–1.907 0.908
*Multivariate logistic regression analysis; CI — confidence interval
0%
MS MVR
67.3%
39%
96.6%
31.5%
87.8%
44.2%
100%
41.7%
AVR MVR + AVR
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heart valvular disease type [13]. Interestingly, 
the group with the lowest rate of therapeutic INR 
achievement was comprised of patients with MVR 
alone. According to the ACCP, therapeutic INR for 
patients with MVR ranges 2.50–3.50, yet 29% of 
these patients had suboptimal INRs ranging 2.00–
–2.49. There are other guidelines that use more 
sophisticated criteria to determine therapeutic INR 
such as the ESC guidelines that subdivides target 
INR levels according to the prosthetic valve’s 
thrombogenicity and clinical risk factors [16]. Yet, 
in our clinical practice our patients are usually not 
aware of the prosthetic valve type that they have, 
which poses a great barrier in determining the 
appropriate INR.
Because patients with valvular AF may be at 
risk of thromboembolic events due to having sub-
-therapeutic INRs, we strived to find a means to 
lower the risk of stroke in these patients. There are 
2 standardized measures to identify stroke risk in 
non-valvular AF that include the CHADSVASC and 
CHADS scores, but no such score exists for valvu-
lar AF [17, 18]. Thus we performed a regression 
analysis using CHADSVASC score parameters. 
Only age was detected as an independent predictor 
of thromboembolic events in patients with valvular 
AF. Specifically, with every year of aging there is 
a 3.4% increased risk of thromboembolism in these 
patients.
Limitations of the study
INR values were not measured at a central 
laboratory. The analysis was based on a cross-
-sectional survey and the prospective data will be 
gathered in the future.
Conclusions
According to the AFTER study, approximately 
20% of AF cases in Turkey were of valvular origin. 
Even though 83.1% of these patients were using 
warfarin, only one-third of them achieved a thera-
peutic INR level. Age was the only independent 
predictor of stroke in this patient group. These 
results suggest that the clinical management for 
anticoagulation in these patients is currently sub-
-optimal. Also more research must be done to 
determine what risk factors predispose valvular 
AF patients to stroke. This way, practice guidelines 
specifically tailored to patients with valvular AF 
may be formulated so that improvements can be 
made in their clinical management.
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